September 3, 2020 – Ortho Clinical Diagnostics (Raritan, NJ) announced that David B. Perez was appointed as an independent member to its board of directors.
Perez is the former president and CEO of Terumo BCT, a $1 billion, mission-driven biomedical company focused on blood and cell-based therapies, and also served on the Terumo Corporation board of directors. Prior to his retirement in early 2019, and throughout his nearly 20-year tenure with Terumo, Perez grew the company from a single manufacturing and R&D site through several foreign ownership structures to a global leader in blood management, blood safety, therapeutic apheresis, cell therapy and cell collections.
The company also announced the appointment of CEO Chris Smith to the additional role of chairman of its board of directors, effective September 1, 2020. Smith, who joined Ortho in September 2019 as CEO, succeeds Robert Yates, who has served as Ortho’s chairman since February 2019. Yates will continue to serve as a member of the board.